Perspective Study of Intensive Therapy Makes Newly Diagnosed Distant Metastatic Nasopharyngeal Cancer (mnpc) Potential Curable.
Tongyu Lin,Mengping Zhang,He Huang,Ying Huang,Chengcheng Guo,Xueying Li,Huangming Hong,Xiaojie Fang,Zhao Wang,Xiaoting Lin,Jia Tian Lin,Chaoyong Liang,Tingzhi Liu,Xiaohong Fu,Shanshan Li,Ying Tian,Pram Raj Shrestha,Yabing Cao,Linzhu Zhai,Taixiang Lu
DOI: https://doi.org/10.1200/jco.2014.32.15_suppl.e17007
IF: 45.3
2014-01-01
Journal of Clinical Oncology
Abstract:e17007 Background: Distant mNPC, commonly treated with platinum-based chemotherapy, is conventionally considered as an incurable disease. We explored the efficacy and survival of cetuximab plus platinum and taxane as induction chemotherapy (IC) followed by CCRT and subsequent maintenance treatment (MT) as 1st-line therapy for mNPC in a perspective study. Methods: Patients (pts) more than 18 ys old with untreated distant mNPC, including initial diagnosis without any prior treatment (IM) and first relapse after radiotherapy (RM), were enrolled in the study. In the pilot treatment group (PTG), pts received IC consisting of cetuximab (initially 400 mg/m2, and then 250 mg/m2 qw), cisplatin (75 mg/m2 q3w), and docetaxel (75 mg/m2 q3w) for a maximum of 6 cycles followed by CCRT (IMRT or tomotherapy to involved primary and cervical fields or bony metastases concurrently with cetuximab and cisplatin) if pts obtained CR/PR after IC, then MT with capecitabine and celecoxib for 3 ys. Contemporaneously, pts treated by other physicians in our center who received platinum-based chemotherapy followed by CCRT according to the NCCN guidelines were considered as control group (CG). Results: 39 pts were enrolled in the PTG from Jul 2006 to Sep 2012 (87% male, median age: 43 ys, 38.5% IM). With a median follow-up time of 23.5 mths, the median OS and PFS were 43.7 mths, 21.0 mths respectively. Subgroup analyses showed pts with IM had a prolonged OS and PFS compared with RM (5yOS: 56.4% vs 32.8%, p=0.021; 5yPFS: 43.2% vs 22.5%, p=0.148). 66 pts in the CG had a poorer survival compared with PTG (5yOS: 13.1%, HR, 0.43, p=0.001; 5yPFS: 5.7%, HR, 0.32, p<0.001). The overall RR of IC was 74% in the PTG and 47% in the CG (p=0.006), which predominately attributed to significant disparity of CR rate (33% vs 3%, p<0.001). No significant differences were observed in the rates of G3/4 AEs during IC between PTG and CG, except for the rate of G3 acne-like rash (10% vs 0%). Conclusions: The favorable increased percentage of pts with newly diagnosed distant mNPC who obtained CR and long-term survival supported a potential curative role for intensive therapy in mNPC. This outcome could be confirmed through further phase III clinical trial.